Results 81 to 90 of about 3,784 (223)

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors [PDF]

open access: yes, 2015
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety.
Bishop, Jeffrey R.   +15 more
core   +1 more source

Obesity‐induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model [PDF]

open access: yes, 2013
BACKGROUND Progressive aging‐ and inflammation‐associated fibrosis effectively remodels the extracellular matrix (ECM) to increase prostate tissue stiffness and reduce urethral flexibility, resulting in urinary flow obstruction and lower urinary tract ...
Adler   +44 more
core   +1 more source

Neuronal human BACE1 knock-in induces systemic diabetes in mice [PDF]

open access: yes, 2016
Acknowledgements The authors thank S. Tammireddy (Diabetes and Cardiovascular Science, University of the Highlands and Islands, Inverness, UK) for technical support with the lipidomics component. Funding We would like to thank R.
Dekeryte, Ruta   +12 more
core   +4 more sources

Detection of TDP-43 seeds in CSF of presymptomatic and symptomatic genetic FTD/ALS. [PDF]

open access: yesAlzheimers Dement
Abstract INTRODUCTION Seed amplification assays (SAAs) have shown promising results in detecting misfolded transactive response (TAR) DNA‐binding protein 43 (TDP‐43) in cerebrospinal fluid (CSF) of genetic frontotemporal dementia (FTD). To date, the use of SAA has yet to be evaluated in presymptomatic individuals.
Dellarole IL   +20 more
europepmc   +2 more sources

From metabonomics to pharmacometabonomics: The role of metabolic profiling in personalized medicine [PDF]

open access: yes, 2016
Variable patient responses to drugs are a key issue for medicine and for drug discovery and development. Personalised medicine, that is the selection of medicines for subgroups of patients so as to maximise drug efficacy and minimise toxicity, is a key ...
Abo   +85 more
core   +2 more sources

Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting [PDF]

open access: yes, 2016
This manuscript provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using
Agúndez, José A.G.   +46 more
core   +1 more source

Optimization of clonazepam therapy adjusted to patient's CYP3A-status and NAT2 genotype. [PDF]

open access: yes, 2017
BACKGROUND: The shortcomings of clonazepam therapy include tolerance, withdrawal symptoms and adverse effects, such as drowsiness, dizziness and confusion leading to increased risk of falls.
Belic Ales   +9 more
core   +1 more source

Fibrosis related inflammatory mediators: Role of the IL-10 cytokine family [PDF]

open access: yes, 2015
Importance of chronic fibroproliferative diseases (FDs) including pulmonary fibrosis, chronic kidney diseases, inflammatory bowel disease, and cardiovascular or liver fibrosis is rapidly increasing and they have become a major public health problem ...
Béres, Nóra   +6 more
core   +5 more sources

Idiopathic rapid eye movement sleep behaviour disorder: a potential gateway to the development of disease-modifying treatments in neurodegenerative disorders [PDF]

open access: yes, 2016
Idiopathic rapid eye movement (REM) sleep behavioural disorder (RBD) is classified as one of the REM parasomnias with clinical characteristics including unpleasant dreams, acting out of dreams, and loss of the typical muscle atonia during the REM phase ...
Peall, Kathryn J., Robertson, Neil
core   +1 more source

Mild motor impairment as prodromal state in amyotrophic lateral sclerosis:A new diagnostic entity [PDF]

open access: yes, 2022
Amyotrophic lateral sclerosis, when viewed as a biological entity rather than a clinical syndrome, probably evolves along a continuum, with the initial clinically silent phase eventually evolving into clinically manifest amyotrophic lateral sclerosis ...
Andersen, Peter M   +7 more
core   +2 more sources

Home - About - Disclaimer - Privacy